Fanlin Kong

FanLin "Emi" Kong is a seasoned regulatory affairs professional with extensive experience in the pharmaceutical industry. Currently serving as Senior Manager at Crinetics Pharmaceuticals since May 2021, responsibilities include compiling, reviewing, and filing investigational new drug applications (INDs) and maintaining development applications. Previously, at Polymed Therapeutics, FanLin managed the drug substance section of a New Drug Application (NDA) that achieved approval without CMC deficiency queries and oversaw multiple drug substances. Earlier roles included regulatory affairs specialist at Polymed Therapeutics, where there was involvement in the submission of Drug Master Files (DMFs) and Certificate of Suitability (CEP) dossiers, as well as a postdoctoral fellowship at MD Anderson Cancer Center focused on the development of radioisotope-labeled compounds for cancer diagnostics. FanLin holds a PhD in Biomedical Sciences from The University of Texas Graduate School of Biomedical Sciences and a BS in Biochemistry from Utsunomiya University.